Mexidol® and Mexidol® Fort 250 as part of the sequential therapy for cognitive disorders in comorbide patients with joint pathology against the background of arterial hypertension and coronary heart disease

L.N. Eliseeva, S.V. Kartashova

FSBEI in Kuban State Medical University of the Ministry of Health of Russia, Krasnodar

Place of publication:
THERAPY No. 6 (40) 2020

Abstract:
The aim of the study was to evaluate the efficacy, safety, and feasibility of correcting the psychoneurological manifestations of chronic cerebral ischemia (CCI) using Mexidol^® and Mexidol^® FORTE 250 as part of sequential therapy for arterial hypertension (AH), atherosclerosis (CAD), osteoarthritis (OA), or rheumatoid arthritis (RA). Material and methods. A total of 134 patients aged 45–75 years with neuroimaging CCI combined with AH, CAD, and joint pathology were examined. Group 1 (observation) included 79 patients: 30 with RA (subgroup 1A) and 49 with OA of the knee joints (subgroup 1B), who received combination therapy with Mexidol^® and Mexidol^® FORTE 250. Group 2 (control) consisted of 55 patients: 25 with RA (subgroup 2A) and 30 with OA (subgroup 2B), who received basic therapy without the addition of Mexidol. The dynamics of subjective and physical symptoms, values ​​​​according to the CGI, MoCA, MFI 20, anxiety and depression scales of Hamilton, Tinnetti were assessed. Mexidol^® was administered intravenously (500 mg daily) for 14 days, followed by oral administration of Mexidol^® FORTE 250 at 250 mg 3 times daily for another 60 days. Results. to standard treatment^® and Mexidol^® as part of sequential therapy contributed to progressive improvement in all studied parameters. Cognitive status remained unchanged in the control groups. The use of initiating intravenous therapy with Mexidol increased patient adherence to long-term use of the drug. Conclusion. Impaired locomotor function in polymorbid patients is partly associated with CCI. The additional administration of sequential infusion and tablet forms of Mexidol significantly improves cognitive functions with correction of gait stability, asthenic manifestations, and increases motivation for active life. Key words: chronic cerebral ischemia, Mexidol^®, Mexidol^® FORTE 250, osteoarthritis, rheumatoid arthritis, arterial hypertension, coronary heart disease.